UP FOR DEBATE SYMPOSIA

NOVARTIS

NEUROENDOCRINE TUMOUR AS AN ONCOLOGICAL ENTITY

Tuesday 12 September 2023, 13:15–14:15 CEST

Hall K, Level -2, Austria Center Vienna, Austria

Promotional symposium organised and funded by Advanced Accelerator Applications International S.A., a Novartis company. This event is for healthcare professionals based outside of the US only.

DR PRAKASH MANOHARAN

The Christie NHS Foundation Trust, Manchester, UK

DR NICOLA FAZIO

European Institute of Oncology, Milano, Italy

DR JAUME CAPDEVILA

Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

AGENDA

TIME (CEST)	SESSION	SPEAKER
13:15–13:25	Welcome and introductions	Dr Prakash Manoharan
13:25–13:35	General criteria for decision-making in patients with advanced GEP-NETS	Dr Nicola Fazio
13:35–14:10	Patient cases *Presentation and panel discussion*	Dr Jaume Capdevila Dr Nicola Fazio
14:10–14:15	Close and thank you	Dr Prakash Manoharan

AAA-Lu177-GL-0516 I August 2023

This promotional event is organised and funded by Advanced Accelerator Applications International S.A., a Novartis company. Adverse events should be reported to Advanced Accelerator Applications International S.A at https://www.novartis.com/report. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the **LUTATHERA**® Summary of Product Characteristics (SmPC) or product information approved in your local country. Full EMA EPAR can be found at: https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera. The SmPC is available at Novartis booth 318.

NAME OF THE MEDICINAL PRODUCT Lutathera 370 MBq/mL solution for infusion **QUALITATIVE AND QUANTITATIVE COMPOSITION** One mL of solution contains 370 MBq of lutetium (^{177}Lu) oxodotreotide at the date and time of calibration. The total amount of radioactivity per single-dose vial is 7 400 MBq at the date and time of infusion. Given the fixed volumetric activity of 370 MBq/mL at the date and time of calibration, the volume of the solution in the vial ranges between 20.5 and 25.0 mL in order to provide the required amount of radioactivity at the date and time of infusion. Physical characteristics: Lutetium-177 has a half-life of 6.647 days. Lutetium-177 decays by β^- emission to stable hafnium-177 with the most abundant β^- (79.3%) having a maximum energy of 0.498 MeV. The average beta energy is approximately 0.13 MeV. Low gamma energy is also emitted, for instance at 113 keV (6.2%) and 208 keV (11%). Excipient with known effect: Each mL of solution contains up to 0.14 mmol (3.2 mg) of sodium. **List of excipients:** Acetic acid, Sodium acetate, Gentisic acid, Ascorbic acid, Pentetic acid, Sodium chloride, Sodium hydroxide, Water for injections; **THERAPEUTIC INDICATIONS** Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults. **CONTRAINDICATIONS** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Established or suspected pregnancy or when pregnancy has not been excluded (see section 4.6). Kidney failure with creatinine clearance <30 mL/min. **PHARMACODYNAMIC PROPERTIES** Pharmacotherapeutic group: Therapeutic radiopharmaceuticals, Other therapeutic radiopharmaceuticals, ATC code: V10XX04 **MARKETING AUTHORISATION HOLDER** Advanced Accelerator Applications, 8-10 Rue Henri Sainte-Claire Deville, 92500 Rueil-Malmaison, France. Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu. Version: 04/2023